Optune is the
first FDA-approved therapy in more than a decade to demonstrate statistically
significant extension of survival in newly diagnosed glioblastoma patients
The EF-14
trial achieved statistically significant extension of both progression-free
survival and overall survival in newly diagnosed glioblastoma with a 50%
increase in the number of patients alive two-years after starting treatment
when treated with TTFields in combination with temozolomide as compared to
temozolomide alone
ST. HELIER,
Jersey, Oct 6 (Bernama-BUSINESS WIRE) -- Novocure (NASDAQ: NVCR) announced today
that the U.S. Food and Drug Administration (FDA) has approved Optune in
combination with temozolomide for the treatment of adult patients with newly
diagnosed glioblastoma (GBM). Optune is a portable, non-invasive device that
delivers low-intensity, intermediate frequency, alternating electric fields –
referred to as Tumor Treating Fields (TTFields) – that inhibit cancer cell
replication and cause cancer cell death.
No comments:
Post a Comment